RxDoctor Payments Data

Dong Wang, MD

Neurology · Duluth, GANPI 1497905913

Payments from drug & device makers

$19,423in general payments, 2019–2025

Across 1,027 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • Novartis$2K
  • EMD Serono, Inc.$955
  • Teva Pharmaceuticals USA, Inc.$878
  • Pfizer$763
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$19,22399%
  • Education$2011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.124$2,077
AbbVie(2 entities)158$1,884
Novartis129$1,858
EMD Serono, Inc.49$955
Teva Pharmaceuticals USA, Inc.35$878
Pfizer57$763
SK Life Science, Inc.31$720
Lundbeck LLC29$719
Biohaven Pharmaceuticals, Inc.15$708
Lilly USA, LLC40$616
Neurocrine Biosciences, Inc.20$601
Amgen23$538
Biohaven Pharmaceutical Holding Company Ltd.52$534
Acadia Pharmaceuticals Inc24$524
Eisai Inc.13$503
Amneal Pharmaceuticals LLC26$484
AstraZeneca(2 entities)7$391
Neurelis, Inc.13$321
Otsuka America Pharmaceutical, Inc.6$298
Sumitomo Pharma America, Inc.10$259
Biogen14$255
Jazz Pharmaceuticals Inc.6$247
Sunovion Pharmaceuticals Inc.9$204
Upsher-smith Laboratories LLC10$198
Boston Scientific3$175
Greenwich Biosciences, Inc.7$162
Sanofi8$153
Impel Pharmaceuticals Inc.3$144
Akcea Therapeutics, Inc.2$142
Scilex Pharmaceuticals Inc.6$121
Harmony Biosciences LLC1$117
ANI Pharmaceuticals, Inc.4$107
Supernus Pharmaceuticals, Inc.6$88
Xeris Pharmaceuticals, Inc.4$81
GE HealthCare2$77
Averitas Pharma Inc.3$71
Aprecia Pharmaceuticals, LLC4$66
Aucta Pharmaceuticals, Inc.3$62
Adamas Pharmaceuticals, Inc.4$60
Axsome Therapeutics, Inc.2$59
Banner Life Sciences, LLC4$59
MDD US Operations, LLC3$57
Avanir Pharmaceuticals, Inc.4$54
Genentech USA, Inc.3$54
Abbott2$52
Alnylam Pharmaceuticals Inc.2$50
Acorda Therapeutics, Inc3$50
Vanda Pharmaceuticals Inc.2$50
Argenx US, Inc.2$49
Grifols USA, LLC2$44
Forte Bio-pharma LLC2$44
CSL Behring2$43
Johnson & Johnson2$39
Kowa Pharmaceuticals America, Inc.2$37
Impel Pharmaceuticals LLC2$36
Avion Pharmaceuticals2$35
Corium, LLC2$35
Mallinckrodt Hospital Products Inc.2$34
Livanova USA, Inc.2$32
Mallinckrodt Enterprises LLC2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,423 in reported general payments places this provider in the 80th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$189,874
Medicare patients
258
Services billed
1,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine38$233,199
AustedoDeutetrabenazine31$226,446
FingolimodFingolimod Hcl13$93,833
UbrelvyUbrogepant44$63,181
BriviactBrivaracetam42$61,970
Nurtec OdtRimegepant Sulfate21$39,697
QuliptaAtogepant21$37,276
FycompaPerampanel19$32,916
RexultiBrexpiprazole19$29,282
Aimovig AutoinjectorErenumab-Aooe30$28,711
RytaryCarbidopa/Levodopa36$25,117
Lacosamide177$22,817
AptiomEslicarbazepine Acetate12$15,335
Levetiracetam297$9,621
Gabapentin561$7,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$878$459,64569 claims
AbbVieUbrelvy, Qulipta$1,884$100,45865 claims
UCB, Inc.Briviact$2,077$61,97042 claims
PfizerNurtec Odt$763$39,69721 claims
Eisai Inc.Fycompa$503$32,91619 claims
Otsuka America Pharmaceutical, Inc.Rexulti$298$29,28219 claims
Amneal Pharmaceuticals LLCRytary$484$25,11736 claims
Sunovion Pharmaceuticals Inc.Aptiom$204$15,33512 claims
Upsher-smith Laboratories LLCTopiramate$198$1,730245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 506 neurology providers in Georgia.

Other neurology in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →